G Protein-Coupled Receptors: What Are They and How Do They Work?

GPCRs play a major role in the psychedelic effect. They also have qualities that make them ideal targets for drug development.


Nature has equipped organisms with a variety of receptors for interacting with their environment. One type of receptor, the G protein-coupled receptor (GPCR), is of particular interest in psychedelic research. The serotonin 5-HT2A receptor, which elicits the psychedelic effect, belongs to the GPCR family. Also, research is revealing the unique role that GPCRs may play when it comes to targeting drugs.

GPCR Basics

The GPCRs are a large and diverse family of proteins. They comprise around 800 members, creating the single largest class of membrane receptors in humans.2 The main function of GPCRs is transducing external stimuli into signals which are then propagated into cells. Inside the cell, the transmitted signal activates signal transduction pathways, resulting in a biological response.

GPCRs respond to a variety of stimuli and activate signaling pathways involving neurotransmitters and hormones.3 They are also mediators for stimuli involving taste, vision, and smell.

GPCRs have a characteristic structure consisting of seven helices that span the cell membrane (Figure 1). Their structure was first resolved in the 1990s using two-dimensional crystals of the rhodopsin.4,5 In 2000, Palczewski et al. published the first crystal structure of bovine rhodopsin.6 The G protein part of the GPCR comes from the fact that each receptor is coupled to a G protein (guanine nucleotide-binding protein) molecule inside the cell.2

Figure 1: An illustration showing how the seven helices of GPCRs span the cell membrane.7

There are five families of GPCRs based on their structural similarities and DNA sequence.8,9 The families form an acronym known as GRAFS: glutamate, rhodopsin, adhesion, frizzled/taste2, and secretin. The rhodopsin family is the largest of the five. The table below, taken from Erlandson et al., lists some examples and functions of the receptors in the GPCR subfamilies.2

The commonalities of GPCRs stand in contrast to the breadth and complexity of their functioning.3

…individual GPCRs have unique combinations of signal-transduction activities involving multiple G-protein subtypes, as well as G-protein-independent signalling pathways and complex regulatory processes.

How GPCRs Work

As discussed earlier, signal transduction in cells is the primary function of GPCRs. The mechanisms of signal transduction are many, and some get quite complex. Briefly, when an agonist binds, the receptor changes conformation (shape).2 The change in shape activates and causes a “dramatic structural rearrangement” in the conformation of the G protein.

There are several types of G proteins, so the downstream signaling pathways from this point depend on which one is coupled to the receptor.10,11 Some of the most well studied GPCR signaling events are the stimulation of the enzyme phospholipase C and the stimulation and inhibition of adenylyl cyclase.12 The signaling initiated by GPCRs is dampened by the action of proteins called arrestins binding to the receptor.13

There is research indicating that single GPCRs are not acting alone or by themselves in producing their effects. In particular, oligomerization of the receptor may play a central role in its activity14-17 (for example, see the rhodopsin receptor complex pictured at the beginning of this article). In a 2002 review paper, George et al. recognized the additional complexity that the concept of oligomerization brings to the study of GPCRs.14

For the future, perhaps the greatest challenge facing the pharmaceutical industry will be to integrate GPCR homo- and hetero-oligomerization (as well as GPCR interactions with other proteins) into the molecular models that are used in the development of novel and improved therapeutics.

Allosteric Modulation

Understanding the phenomenon of allosteric modulation (AM) is essential for getting the full picture of GPCR functioning. The mechanics of AM sound simple. Basically, a ligand binds at a site (the allosteric site) other than the orthosteric (primary) binding site.18 After the AM binds, things get a little more complicated.

The binding of AMs causes conformational changes in the receptor and other alterations in the receptor state. These alterations change in how the receptor interacts with the endogenous ligand (the molecule that binds to the orthosteric site), an agonist, or antagonist. There are positive AMs (PAMs) that increase the affinity, efficacy, or both of the receptor for the endogenous ligand. Negative AMs (NAMs) decrease these properties.

In their 2018 paper, Erlandson et al. called GPCRs “complex allosteric machines.” 2 The authors state that GPCRs “…are networks of allosterically linked structural switches.” They explain that only does AM affect the GPCRs themselves, but also other molecules like the G proteins and arrestins.

In 2009, Conn et al. stated the following regarding allosteric compounds of GPCRs that have been developed,19

These compounds provide high selectivity, novel modes of efficacy, and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

Targeting allosteric sites on GPCRs presents many opportunities for drug exploration. Although AM is not unique to GPCRs, they are by far the largest class of targets for modern-day drugs.14 When it comes to the entourage effect in naturally occurring psychedelic cocktails, this adds another deep layer of complexity and mystery for scientific study.

More Research is Needed on GPCRs and Psychedelics

GPCRs are intimately involved in the psychedelic effect. However, scientists still don’t understand how the entourage effect may influence the effects of nature’s psychedelic cocktails. On top of that, the likelihood of AM also influencing the effects of psychedelics at GPCRs is creating more research opportunities.

For those interested in all things GPCR, check out the GPCR database maintained by the University of Copenhagen.

Barb Bauer Headshot

Barb is the former Editor and one of the founders of Psychedelic Science Review. She is currently a contributing writer. Her goal is making accurate and concise psychedelic science research assessable so that researchers and private citizens can make informed decisions.


Notify of

Inline Feedbacks
View all comments
  1. Zhou XE, Gao X, Barty A, et al. X-ray laser diffraction for structure determination of the rhodopsin-arrestin complex. Scientific Data. 2016;3(1):1-13. doi:10.1038/sdata.2016.21
  2. Erlandson SC, McMahon C, Kruse AC. Structural Basis for G Protein–Coupled Receptor Signaling. Annu Rev Biophys. 2018;47(1):1-18. doi:10.1146/annurev-biophys-070317-032931
  3. Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-363. doi:10.1038/nature08144
  4. Krebs A, Villa C, Edwards PC, Schertler GFX. Characterisation of an improved two-dimensional p22121 crystal from bovine rhodopsin. Journal of Molecular Biology. 1998;282(5):991-1003. doi:10.1006/jmbi.1998.2070
  5. Schertler GFX, Villa C, Henderson R. Projection structure of rhodopsin. Nature. 1993;362(6422):770-772. doi:10.1038/362770a0
  6. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289(5480):739–745.
  7. Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. Journal of Cell Science. 2003;116(24):4867-4869. doi:10.1242/jcs.00902
  8. Fredriksson R, Lagerström MC, Lundin L-G, Schiöth HB. The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints. Mol Pharmacol. 2003;63(6):1256-1272. doi:10.1124/mol.63.6.1256
  9. Schiöth HB, Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. General and Comparative Endocrinology. 2005;142(1):94-101. doi:10.1016/j.ygcen.2004.12.018
  10. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends in Pharmacological Sciences. 2001;22(7):368-376. doi:10.1016/S0165-6147(00)01678-3
  11. Neves SR. G Protein Pathways. Science. 2002;296(5573):1636-1639. doi:10.1126/science.1071550
  12. McCorvy JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics. 2012. https://search.proquest.com/docview/1237241775. Accessed May 2, 2019.
  13. Ferguson SSG. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological reviews. 2001.
  14. George SR, O’Dowd BF, Lee SP. G-Protein-coupled receptor oligomerization and its potential for drug discovery. Nature Reviews Drug Discovery. 2002;1(10):808-820. doi:10.1038/nrd913
  15. Palczewski K. Oligomeric forms of G protein-coupled receptors (GPCRs). Trends Biochem Sci. 2010;35(11):595-600. doi:10.1016/j.tibs.2010.05.002
  16. Maurel D, Comps-Agrar L, Brock C, et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods. 2008;5(6):561-567. doi:10.1038/nmeth.1213
  17. Albizu L, Cottet M, Kralikova M, et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology. 2010;6(8):587-594. doi:10.1038/nchembio.396
  18. Christopoulos A, Changeux J-P, Catterall WA, et al. International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands. Ohlstein EH, ed. Pharmacological Reviews. 2014;66(4):918-947. doi:10.1124/pr.114.008862
  19. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8(1):41-54. doi:10.1038/nrd2760